Abstract
Aims
To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.
Methods
Case note review. Main outcome measure was recurrence of uveitis.
Results
All patients remained free of recurrence with stable visual acuities.
Conclusions
Adalimumab appears to maintain disease remission in Behçet's disease.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Murray PI, Sivaraj RR . Anti-TNF-α therapy for uveitis: Behçet and beyond. Eye 2005; 19: 831–833.
Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN . Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295–296.
Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362–1368.
Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP . Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004; 138: 648–650.
Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123: 903–912.
Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthr Rheum 2005; 52: 2478–2484.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mushtaq, B., Saeed, T., Situnayake, R. et al. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 21, 824–825 (2007). https://doi.org/10.1038/sj.eye.6702352
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6702352
Keywords
This article is cited by
-
Shaping the Future of Behçet’s Uveitis Management: A Comprehensive Review of Efficacy, Challenges, and Prospects of Biologic Therapies
Ophthalmology and Therapy (2023)
-
Fluorescein angiographic findings and Behcet's disease ocular attack score 24 (BOS24) as prognostic factors for visual outcome in patients with ocular Behcet's disease
International Journal of Retina and Vitreous (2021)
-
An Overview of Conventional and Recent Treatment Options for Behcet’s Disease
Current Treatment Options in Rheumatology (2020)
-
Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet’s disease-related uveitis
Journal of Ophthalmic Inflammation and Infection (2019)
-
Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study
Clinical Rheumatology (2017)
